Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ADARx Pharmaceuticals, Inc.

NASDAQ: ADRX · Life Sciences · 8 alerts · CIK 1802369

Share price
$14.00Close, Nov 16
Market cap
$1.56B
Shares outstanding
111.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ADARx Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:16 PM ET 10-Q
Financial Results

ADARx Pharmaceuticals Q3 2026 Results: Net Loss of $28.1M, Loss Widens

ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.

Key figure
Net loss $28.1M
4:07 PM ET 8-K
Financial Results

ADARx Pharmaceuticals Financial Results

ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx

“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.